Vector450

Vector450 is a preclinical-stage biotechnology company specializing in the development of a proprietary protein-based delivery platform for targeted therapeutics. The company's core technology is engineered to bypass the liver—a common site of off-target accumulation—and deliver payloads directly to specific organs, with a primary focus on the lungs. This tissue-specific targeting is achieved through the use of unique protein vectors that recognize specific vascular or cellular markers. Vector450's approach aims to improve the safety and potency of various modalities, including gene therapies and biologics, for treating oncology and inflammatory respiratory conditions. The company was founded by researchers from Washington University in St. Louis and is currently advancing its platform toward clinical applications.